AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05637502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery
Description: Graded Motor Imagery programme consisting on three stages that will be gradually implemented. (i) Implicit Motor Imagery, that will be implemented through a developed app that resembles the Recognize app but adapted for Pelvic Floor disorders, (ii) Explicit Motor Imagery, applied through several sessions of motor imagery assisted through audio recordings and (iii) Graded Exposure, also guided through audio recordings and several practical tasks to perform.
Study NCT04119934 — intervention group
Intervention type: BEHAVIORAL
Intervention: Smoking Cessation Intervention Tool
Description: A personalized smoking cessation infographic is provided to the physician/NP alongside the patient's regular spirometry report.
Study NCT06213116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MADgic Atomizer
Description: Device to deliver directly lignocaine
Study NCT06213116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine pump spray
Description: Lignocaine 30 mg (3 puffs) given via 10mg Lignocaine Pump Spray prior to endotracheal intubation
Study NCT06251804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exercise program
Description: The exercise program includes a short foot exercise and will be given in water.
Study NCT06251804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land-based-program
Description: The exercise program includes a short foot exercise and will be given on land.
Study NCT04745117 — intervention group
Intervention type: BEHAVIORAL
Intervention: READHY - questionnaire
Description: The READHY tool consists of 70 questions divided into three sections, one with a focus on eHealth literacy, one on self-management and one on the social context. The READHY consists of the eHealth Literacy Questionnaire (eHLQ) that includes seven scales, supplemented with four scales from the Health Education Impact Questionnaire (heiQ) and two scales from the Health Literacy Questionnaire (HLQ). The READHY tool has been validated. Each question presented to the participant as a statement and scored on a 4-point rating, from 1=strongly disagree to 4=strongly agree. The overall score of each scale was calculated as the mean score of the 4-6 items (i.e., statements) that constitute the scale (2).
Study NCT06427499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Description: brush 2 min morning \& night daily
Study NCT06427499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection Toothpaste
Description: brush 2 min morning \& night daily
Study NCT04258072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-(\[1,2,4\]triazolo\[1,5-a\]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight
Study NCT05328960 — intervention group
Intervention type: OTHER
Intervention: Diagnosed during or not during the pandemic
Description: We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
Study NCT04997304 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AirDuo Digihaler
Description: Patients will receive the AirDuo® Digihaler™ at a dose that is equivalent to the patients current inhaled therapy dose. Most patients will likely require the high dose inhaler: 232/14 device. This medication will be administered twice daily. The study and treatment will last 1 year.~Participants will also use a home spirometry device and smart device application (app) will be used to track medication usage and allow users to self-assess their respiratory symptoms on a daily basis.
Study NCT04997304 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ProAir Digihaler
Description: Patients will receive the ProAir® Digihaler™ 90mcg at a dose that is equivalent to the patients current inhaled therapy dose. Most patients will likely require the high dose inhaler: 232/14 device. The ProAir® Digihaler™ will be utilized up to six times per day as needed for acute asthma symptoms. The study and treatment will last 1 year.
Study NCT05716347 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
Description: one booster dose intramuscularly in the deltoid muscle of the upper arm.
Study NCT05716347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
Description: one booster dose intramuscularly in the deltoid muscle of the upper arm.
Study NCT04724135 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The first part will assess the sociodemographic variables and reproductive characteristics, and the second part contain the Menopause-Specific Quality of Life (MENQOL) questionnaire The 29 questions of the MENQOL are divided into four domains: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29).
Study NCT05944640 — intervention group
Intervention type: PROCEDURE
Intervention: Intraocular surgery
Description: Pars plana vitrectomy or cataract surgery.
Study NCT05074329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moventis PNS
Description: Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
Study NCT05074329 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Moventis PNS
Description: Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
Study NCT06349876 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic cholecystectomy
Description: slandered laparoscopic cholecystectomy
Study NCT04773275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electric field treatment using the Aliya system
Description: Patients will undergo pulsed electric field (PEF) treatment of up to 5 tumors (new or progressing) measuring ≤ 2cm in longest diameter.
Study NCT04580927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding self-efficacy (BSE)
Description: Self-efficacy is determined by factors such as prior experience, vicarious learning, persuasion of others and physiological state, which in turn impact on one's behaviours and actions. One's sense of self-efficacy is modifiable, and can be readily targeted for intervention. An increasingly studied key determinant of breastfeeding outcomes is breastfeeding confidence, also referred to as breastfeeding self-efficacy (BSE). The investigators will use a nurse-administered validated BSE intervention tool.
Study NCT04819776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Oral iloperidone
Study NCT04819776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iloperidone Placebo
Description: Oral placebo
Study NCT05657652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine, cytarabine,venetoclax
Description: Cladribine 5 mg/m2/day, cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
Study NCT05174936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLWH intervention
Description: The intervention curriculum will consist of five interactive training sessions (2 hours each) with four specific areas of resilience-building: individual assets (self-esteem, emotion regulation, positive future orientation), coping with infection/illness (medical adherence, stress reduction, healthy lifestyle, self-care), relationship building (family relationship, provider-patient relationship), and social support (identifying and seeking social support at various socioecological levels).
Study NCT05174936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family member intervention
Description: The intervention will consist of five sessions of group activities (2 hours each), with each session addressing one or more of the following areas: 1) HIV and ART knowledge; 2) support to strengthen the capacity of PLWH and their family members to adapt to living with HIV; 3) relationship building (family relationships, intimate relationships); 4) emotional and behavioral support for PLWH's adherence to care and treatment, including tailored coping or support strategies to address unique needs of some participants who may be more prone to HIV stigma (e.g., MSM and their family members); and 5) self-care.
Study NCT05174936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare provider intervention
Description: The HCP intervention will adapt Popular Opinion Leaders (POL) principles by teaching participants skills for initiating/disseminating stigma reduction messages/practices to colleagues in the workplace. The HCP intervention will consist of four 1.5-hour sessions addressing the following topics: 1) universal HIV precautions and occupational safety (e.g., correctly knowing and practicing universal precautions and decreasing fear of PLWH); 2) intersecting stigma against PLWH (e.g., manifestations of intersecting stigma in clinical settings); 3) provider-patient relationship (e.g., reducing stigmatizing attitudes and behaviors toward PLWH, respecting patients' rights for privacy related to care and disclosure); 4) improving quality of patient care (e.g., increasing skills and comfort in working with PLWH); 5) building a supportive medical environment for better care of PLWH; and 6) skills and confidence in delivering stigma reduction messages to coworkers.
Study NCT05003609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Rehabilitation
Description: The intervention involves a progression of rehabilitation exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 mins) at each session. The intervention will be administered 5 days per week (weekdays) while the patient remains in ICU, censored at 28 days after randomisation.
Study NCT06267092 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No treatment given
Description: Participants will not get any medicine during this study.
Study NCT06267092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide and Semaglutide
Description: Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.
Study NCT06267092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
Study NCT05101148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: The dosing regimen for selumetinib (25 mg/m2 bid) will be based on BSA, during T1 and T2 the dose will be 25mg/m2, consistent with the approved prescribing information in the US. If T3 is required, appropriate dose of selumetinib will be defined by Data Review Committee for T3.
Study NCT05936359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.
Study NCT05936359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Rux will be administered according to Prescribing Information/SmPC.
Study NCT05822830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT05822830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Administered SC
Study NCT05628168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic Mobilization Techniques
Description: The slider neurodynamic technique for the median nerve is conducted.Tensioner neurodynamic technique for the tibial nerve is conducted.
Study NCT05628168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Physical Therapy Program
Description: The participants only received a selected therapy program similar to the NMG with no change in duration.
Study NCT05628168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selected Physical Therapy Program
Description: The participants only received a selected therapy program similar to the NMG with no change in duration.
Study NCT05898035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic Microsurgery
Description: Osteotomy will be done either with air motor high speed hand-piece and round bur with copious irrigation or with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex , the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth at ( 0 - 10) degree bevel , using either conventional dental hand-piece or piezotome (Piezotome Cube by ACTEON ).The resected root will be rinsed , dried and and stained with 1% methylene blue dye after which , it will be inspected carefully under high magnification, to identify possible reasons for the non surgical root canal treatment failure. Subsequently, ultrasonic apical preparation will be performed. After achieving adequate haemostasis with Epinephrine pellets. Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament size 5-0 suture will be applied. Finally, Post-operative parallel Digital view.
Study NCT05898035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic Microsurgery
Description: Osteotomy will be done either with air motor high speed hand-piece and round bur with copious irrigation or with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex , the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth at ( 0 - 10) degree bevel , using either conventional dental hand-piece or piezotome (Piezotome Cube by ACTEON ).The resected root will be rinsed , dried and and stained with 1% methylene blue dye after which , it will be inspected carefully under high magnification, to identify possible reasons for the non surgical root canal treatment failure. Subsequently, ultrasonic apical preparation will be performed. After achieving adequate haemostasis with Epinephrine pellets. Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament size 5-0 suture will be applied. Finally, Post-operative parallel Digital view.
Study NCT05641571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The home-based extremity exercise program
Description: Participants have to perform a total of 50 minutes of exercise including the Ten Skilled Hand exercise fourth a day, 5 minutes each time and Buerger Allen exercise twice a day, 15 minutes each time before chemotherapy to the completion of chemotherapy.
Study NCT06487429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab
Description: Short range radiotherapy, PCTV (clinical planned target area) DT 25Gy/5F, once a day, for a total of 5 days, continuous irradiation, and IMRT (intensity modulated radiation therapy) technology; After a week of rest, radiotherapy and chemotherapy combined with immunotherapy will be performed~* Disitamab Vedotin: 2.5 mg/kg, intravenous infusion, d1, Q3W;~* Sintilimab: 200mg, iv;~* S-1: 40 mg/dose, oral, bid, d1-14; Q3W Whether to undergo adjuvant therapy after surgery is determined by the researcher
Study NCT04577066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GA2
Description: 15 volunteers will receive 50 GA2-infected mosquito bites. The GA2 parasite is a new genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and should not be able to cause malaria in humans.
Study NCT04577066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GA1
Description: 10 volunteers will receive 50 GA1-infected mosquito bites. The GA1 parasite is a genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and is not able to cause malaria in humans.
Study NCT04577066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 volunteers will receive 50 uninfected mosquito bites.
Study NCT05871307 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative Radiotherapy
Description: Resection of brain mestases following
Study NCT05871307 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiation
Description: While Resection
Study NCT05871307 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Radiotherapy
Description: After resection
Study NCT06094816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide (Diuretic)
Description: The diuretic furosemide will be given during a 3% hypertonic saline infusion to examine blockade of the NKCC2.
Study NCT06094816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline Infusion
Description: 3% Hypertonic saline infusion to acutely increase sodium and osmolality
Study NCT06221709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Radiofrequency (CRF group)
Description: Radiofrequency will be performed with a 22-gauge CRF cannula, 10/15 cm long, 10mm curved active tip, at 90º for 90 seconds, introduced in the anteroposterior and lateromedial directions, to reach the teardrop landmark. Denervation of the articular branches of the Obturator Nerve will be performed in 2 cycles, starting lateral to the lateral edge of the obturator foramen, followed by a point approximately 1cm lateral to the first point. Next, the cannula will be repositioned in a more cranial location, parallel to the superolateral edge of the acetabular dome, to reach the sensory branches of the Femoral Nerve, performing 3 cycles at the 01, 12, and 11 o'clock positions. All lesions will be preceded by motor stimulation at 2,5V and cycles will be followed by the infusion of 2ml of 1% ropivacaine. After concluding the procedure, hip intraarticular infiltration will be performed as described for the control group.
Study NCT06221709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular Infiltration ( Control group)
Description: For the control group (IA), an epidural anesthesia needle (22G spinal needle) will be used, positioned anteroposteriorly towards the central portion of the femoral neck, which will be introduced until transfixion of the anterior hip capsule through tactile sensitivity. After checking the correct positioning with the use of fluoroscopy and infusion of 3 ml of 50% diluted iodinated contrast, an infusion of 4 ml of 1% Ropivacaine and 80mg of methylprednisolone 40mg/ml will be done.
Study NCT05661448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: The goal of this program is to improve performance on cognitive domains known to hinder functioning. It aims to promote positive attitudes towards learning and facilitate the development of independent learning skills to foster competence and confidence. Another aim is to increase patients' awareness of their cognitive strengths and weaknesses and their own problem solving strategies.
Study NCT05661448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MetaCognitive Training
Description: The metacognitive training (MCT) program is based on the theoretical foundations of cognitive models of schizophrenia but employs a slightly different focus in its therapeutic approach targeting the specific cognitive biases underlying delusions. The modules aim to raise awareness of these biases and prompts participants to critically reflect on and update their problem-solving repertoire.
Study NCT04744298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraPPP
Description: TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning.
Study NCT04072874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental topical (Curaleish Topical)
Description: Curaleish is a formulation in lotion and cream. Curaleish lotion and Curaleish cream will be applied topically by each participant in all lesion until day 28 or 42, depending on the regimen to be evaluated. Study staff will be closely observing the safety assessment. The application until Day 28 or 42 will continue, even if the lesion has shown 100% re-epithelization before day 28 or day 42.
Study NCT06297759 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Sense of Competence in Dementia Care Staff (SCIDS) Scale
Study NCT01028313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: 20 mg PO three times weekly
Study NCT01028313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1 mg/kg/day PO continuously
Study NCT06533059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTA2618
Description: Oral ALTA2618 tablets will be administered at protocol-defined dose
Study NCT05593445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study NCT05593445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle cream
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study NCT05593445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study NCT06598410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital gaming
Description: Children in this group will be allowed to play digital games 5 minutes before the procedure starts. They will continue to play the game during the procedure.